Fig. 1

LINC01559 is expressed at higher levels in LUADs with metastasis and is associated with poor patient outcome. A Analysis of a published gene expression microarray dataset for treatment-naïve NSCLC (GSE11117) showing that the lncRNAs HAND2-AS1, GLIS3-AS1, MRVI1-AS1, LINC00612, and LINC01559 were expressed at higher levels in bronchoscopic biopsy tissues from LUADs with metastatic lesions compared to those without. Two-tailed Student’s t-test. B Kaplan-Meier analysis of the probability of overall survival of LUAD patients (n = 453) derived from the TCGA datasets. The log-rank test. C LINC01559 was expressed at higher levels in LUAD tissues (n = 58) compared to paired adjacent normal tissues (n = 58) in the TCGA database. Two-tailed Student’s t-test. D and E Representative microphotographs (D) and quantitation (E) of in situ hybridization (ISH) analysis of LINC01559 expression in formalin-fixed paraffin-embedded (FFPE) lung adenocarcinoma (n = 90 biologically independent samples) compared with paired adjacent normal tissues. Scale bar, 10 µm. RS: reactive score. Two-tailed Student’s t-test. F Kaplan-Meier analysis of the probability of overall survival of LUAD patients (n = 90) stratified according to the expression of LINC01559 as shown in D and E. The log-rank test. G qPCR analysis of LINC01559 expression in the indicated LUAD cell lines and the human fibroblast cell line HSF. Data are mean ± s.d.; n = 3 independent experiments, one-way ANOVA followed by Tukey’s multiple comparisons test